CELC Options Surge as Stock Falls 17% on the Week

Celcuity heads into the final stretch before its November 13 earnings with a striking contradiction: the options market is showing its most bullish tilt in weeks, even as the stock posts one of its worst weekly performances of the year.

The most unusual signal right now is in options positioning. Call demand has surged to the point where the put/call ratio has dropped to 0.34, more than two standard deviations below its 20-day average of 0.47. That makes this one of the most skewed-call readings of the past year, with the 52-week low sitting at 0.09 and the high at 1.04. The timing is striking given the price action: CELC fell 6.2% on Friday alone and is down 16.7% on the week to $56.58, and off 31.6% over the past month. Options buyers are leaning into a sharp move lower as a buying opportunity rather than hedging against further downside, though the direction this positioning resolves remains open.

Short interest tells a more structurally cautious story. At 22.4% of the free float, short positioning is elevated but has been unwinding. The short base has fallen around 8.4% over the past week, and is down from highs seen in late September when shares outstanding on loan ran above 11.6 million. Borrow conditions are not the reason to worry: availability is ample at 312%, meaning there are roughly three shares available to borrow for every two already lent out, well off the tightest reading of the past 52 weeks at 69%. The cost to borrow is a nominal 0.56%, barely changed on the week. The ORTEX short score, at 70.2, is elevated but has eased from a recent peak near 75 in early October, tracking the modest short-covering trend. Positioning looks cautious but not crowded, and the lending market presents no near-term squeeze risk.

The Street remains firmly bullish despite the sell-off, though the gap between analyst targets and the current price deserves a caveat. The consensus is Buy across all recent actions, with JP Morgan initiating at Overweight with a $157 target in September and Needham trimming its target modestly to $134 at end of September while keeping its Buy rating. Guggenheim was more bullish in August, raising to $175. Even the lowest recent target is more than double Friday's close at $56.58. The mean target is around $157, implying close to 180% upside if taken at face value, but targets of that magnitude relative to a current price often reflect a stock that has de-rated sharply since the targets were set rather than a near-term price call. The bear case centers on a binary clinical and regulatory story: gedatolisib must prove itself across multiple trials, the company will need more equity capital, and larger-resourced rivals are competing in the same HR+/HER2- space. The bull case rests on the breadth of PI3K/mTOR inhibition, the REVTORPYK commercial launch expected around late third quarter 2026, and a $754 million cash balance reported at end of Q2 that funds operations into beyond 2029.

The ownership picture adds another layer of complexity. Baker Bros. Advisors, registered on the 13D activist register with roughly 10% of the class as last disclosed, sold a combined $318 million worth of CELC shares in July at around $102.50 per share. That filing was made in July, when the stock was trading at roughly double the current price. Net insider activity over the past 90 days is sharply negative at approximately minus $318 million in value, driven almost entirely by that sale. The grant-type transactions for the CEO, CFO and CSO in August carry no stated price and represent compensation mechanics rather than market conviction. Growth Equity Opportunities 18 VGE, another 13D registrant, has already reduced its stake from 6.3% to 4.9% as last disclosed in March, meaning it may now sit below the 5% threshold without any obligation to file again. Stakes are as last disclosed around that threshold; positions can change without further notice. BlackRock, Vanguard and State Street all added shares at the September quarter end, providing some institutional ballast, but the weight of the big insider sale from July hangs over the register. Retail attention, meanwhile, has spiked sharply: the ORTEX Wikipedia pageviews signal is running at a z-score of 6.2, well above the prior 90-day average, suggesting the price drop has drawn significant non-institutional interest.

Correlation across the peer group is worth noting. Close comps OLMA and IMNM both fell around 15% to 16% on the week, suggesting some of the CELC move reflects sector-wide pressure rather than stock-specific news. With earnings on November 13, the next question is whether the call-heavy options positioning, the retreating short base, and the persistent analyst Buy consensus hold up as the company approaches its next data release.